SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)

Summary

The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.

Timeline

Start

2004-04

Primary completion

2007-09

Completion

2007-09

Publications

• Background Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, Mondadori CG, Pearlman R. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87. doi: 10.1016/j.bcp.2004.07.030.

Drugs

Indications